摘要
在核苷和核苷酸类药物（nucleoside and nucleotide analogs，NAs）治疗慢性乙型肝炎过程中，耐药是一个极为重要的问题。与未发生耐药的患者比较，耐药不仅可导致疾病进一步进展，并可增加发生肝功能失代偿和肝细胞癌（HCC）的风险；还会加大后续治疗的难度，增加长期治疗的医疗成本。
Four nucleos(t)ide analogs(NAs)have been approved by the Food and Drug Administration,China for treatment of patients with chronic hepatitis B(CHB).The patients can be successfully treated using nucleos(t)ide analogs(NAs),but drug-resistant hepatitis B virus(HBV)mutants frequently arise,leading to treatment failure and progression of the disease.This paper has reviewed the mechanisms of resistance to NAs,and consensus on the management and prevention of HBV resistance to NAs.
出处
《临床肝胆病杂志》
CAS
2013年第1期10-17,共8页
Journal of Clinical Hepatology
关键词
肝炎
乙型
慢性
抗药性
核苷和核苷酸类药物
管理
hepatitis B, chronic
drug resistance
nucleoside and nucleotide analogs
management
